Sanofi Pasteur's dengue vacc enters clinical development

Sanofi Pasteur, the vaccines division of French drug major Sanofi-Aventis, says that its investigational tetravalent Dengue vaccine  is entering into a pediatric clinical study in Thailand to assess its  efficacy in protecting children against Dengue, which is the most  widespread tropical disease after malaria. Sanofi's vaccine candidate is  the first to reach this stage of clinical development. The firm is  collaborating with Mahidol University of Thailand, the Ministry of  Public Health and the Pediatric Dengue Vaccine Initiative to conduct  this efficacy study in the province of Ratchaburi. Sanofi's clinical  study program follows guidelines from the Initiative for Vaccine  Research led by the World Health Organization, which fosters the global  effort towards Dengue vaccine development.